Evotec stock trades on its latest reported results
Published on 07/25/2026 at 20:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec (ISIN DE0005664809) is best framed by its latest reported numbers: the Hamburg-based drug discovery group posted revenue of EUR 797.0 million in 2024, reported EBITDA of EUR -55.8 million, and ended 2024 with net income of EUR -426.6 million.
Those figures matter because 2024 revenue was 4.1% lower than 2023, while the EBITDA and net income lines showed the pressure still flowing through the business model. For Evotec stock, that combination of scale, loss-making profitability, and a still-subdued top line is the main reference point for any current reading.
Revenue and profit pressure
Evotec said 2024 revenue came in at EUR 797.0 million, compared with EUR 831.5 million in 2023. The move represents a drop of EUR 34.5 million year on year, which is a concrete 4.1% decline.
EBITDA was EUR -55.8 million in 2024, versus EUR 46.3 million in 2023, a swing of EUR 102.1 million. Net income moved to EUR -426.6 million from EUR -109.2 million a year earlier, showing how quickly the bottom line deteriorated.
Losses widen
That earnings profile is the key lens for investors reading Evotec stock now. A company with EUR 797.0 million in annual revenue can still look fragile if EBITDA stays negative and net income reaches EUR -426.6 million.
The same 2024 report also shows why balance-sheet and cash-flow discipline matter. With losses at that scale, the next reported period will be judged less on headlines and more on whether operating metrics improve in a measurable way.
Evotec annual report numbers
A closer look at the 2024 report helps put the latest revenue and profit trend in context.
Evotec revenue at EUR 797.0 million
One representative product line for the group is its discovery and development platform, which underpins partnerships across small molecules and biologics. That platform matters because 2024 revenue of EUR 797.0 million only has value if the partnering engine continues to convert into paid projects and milestone income.
The 2024 report numbers show the commercial base remains meaningful, but the profitability bridge is still the issue. Revenue of EUR 797.0 million, EBITDA of EUR -55.8 million, and net income of EUR -426.6 million together describe a business that is still working through a reset.
Market context
As of 25 July 2026, Evotec stock is best read through those 2024 results rather than a short-term price move. The stock article therefore centers on the most recent evidenced operating figures, which are enough to show the scale of the challenge even without a fresh trading print.
The latest available market frame and the 2024 report both point in the same direction: the company remains large enough to matter, but the profit line has not yet caught up with the revenue base.
Evotec fact box
- Company: Evotec SE
- ISIN: DE0005664809
- Ticker: XETRA: EVT
- Trading venue: Xetra
- Sector / Industry: Health Care / Biotechnology
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
